| Title |
Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion
|
|---|---|
| Published in |
World Journal of Urology, July 2011
|
| DOI | 10.1007/s00345-011-0721-0 |
| Pubmed ID | |
| Authors |
Bertrand Tombal, Filip Ameye, Alexandre de la Taille, Theo de Reijke, Paolo Gontero, Alexander Haese, Paul Kil, Paul Perrin, Mesut Remzi, Jörg Schröder, Mark Speakman, Alessandro Volpe, Bianca Meesen, Herman Stoevelaar |
| Abstract |
The Prostate CAncer gene 3 (PCA3) assay may guide prostate biopsy decisions and predict prostate cancer (PCa) aggressiveness. This study explored the appropriateness of (1) PCA3 testing; (2) biopsy; (3) active surveillance (AS) and the value of the PCA3 Score for biopsy and AS decisions. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 18% |
| Student > Master | 4 | 18% |
| Student > Bachelor | 2 | 9% |
| Other | 2 | 9% |
| Researcher | 2 | 9% |
| Other | 4 | 18% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 45% |
| Agricultural and Biological Sciences | 3 | 14% |
| Computer Science | 2 | 9% |
| Unknown | 7 | 32% |